MLYNARSKI, SCOTT NATHAN,玛莲那斯基 史考特 纳森,瑪蓮那斯基 史考特 納森,GREBE, TYLER,葛理柏 泰勒,KAWATKAR, SAMEER,卡渥卡尔 赛米尔,卡渥卡爾 賽米爾,FINLAY, MAURICE RAYMOND VERSCHOYLE,芬莱 慕里斯 雷蒙 佛斯裘尔,芬萊 慕里斯 雷蒙 佛斯裘爾,SIMPSON, IAIN,辛浦森 艾恩,辛浦
申请号:
TW108105043
公开号:
TW201945004A
申请日:
2019.02.15
申请国别(地区):
TW
年份:
2019
代理人:
摘要:
Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is -NHR1a; R1a is -H or -C(O)CH(R1b)NHR1c; and R1b is selected from -H, -(C1-C4) alkyl and CH2OR1d and R1c is -H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or -CH3.揭露了式(Ia)之化合物或其藥學上可接受的鹽、包含式(Ia)之化合物之藥物組成物以及使用它們治療癌症或呼吸道炎性疾病和抑制精胺酸酶之方法: 其中R1為-NHR1a;R1a為-H或-C(O)CH(R1b)NHR1c;並且R1b選自-H、-(C1-C4)烷基和CH2OR1d,並且R1c為-H;或R1b和R1c與它們所連接的原子一起形成5員雜環;並且R1d為H或-CH3。